Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd-R Burmester

Showing results (51-60 of 293) with videos related to

Pageof 30
Sort By:
Rheumatology and Therapy|January 12, 2026
Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA)Georg Pongratz, Rieke Alten, Torsten Witte, et al.
Annals of the Rheumatic Diseases|May 15, 2020
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA studyPaul Emery, Gerd R Burmester, Esperanza Naredo, et al.
Arthritis and Rheumatism|June 28, 2006
Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28Michael Brychcy, Ulrike Kuckelkorn, Gert Hausdorf, et al.
Annals of the Rheumatic Diseases|August 31, 2011
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteriaChristof Iking-Konert, Martin Aringer, Jürgen Wollenhaupt, et al.
The Journal of Rheumatology|March 17, 2019
Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study SubanalysisJürgen Braun, Xenofon Baraliakos, Uta Kiltz, et al.
Clinical and Experimental Rheumatology|April 24, 2010
Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)Christopher Schneeweis, Michael Rafalowicz, Eugen Feist, et al.
Arthritis Research & Therapy|January 28, 2014
Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational studyGerd R Burmester, Marco Matucci-Cerinic, Xavier Mariette, et al.
Arthritis Research|July 11, 2002
Analysis of immunoglobulin light chain rearrangements in the salivary gland and blood of a patient with Sjögren's syndromeAnnett M Jacobi, Arne Hansen, Olaf Kaufmann, et al.
Journal of Biomolecular Screening|March 24, 2007
Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugsThomas Häupl, Mehdi Yahyawi, Carsten Lübke, et al.
European Journal of Immunology|August 30, 2017
Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritisSarah Fleischer, Stefanie Ries, Ping Shen, et al.
Pageof 30

Showing results (51-60 of 293) with videos related to

Sort By:
Pageof 30
Rheumatology and Therapy|January 12, 2026
Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA)Georg Pongratz, Rieke Alten, Torsten Witte, et al.
Annals of the Rheumatic Diseases|May 15, 2020
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA studyPaul Emery, Gerd R Burmester, Esperanza Naredo, et al.
Arthritis and Rheumatism|June 28, 2006
Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28Michael Brychcy, Ulrike Kuckelkorn, Gert Hausdorf, et al.
Annals of the Rheumatic Diseases|August 31, 2011
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteriaChristof Iking-Konert, Martin Aringer, Jürgen Wollenhaupt, et al.
The Journal of Rheumatology|March 17, 2019
Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study SubanalysisJürgen Braun, Xenofon Baraliakos, Uta Kiltz, et al.
Clinical and Experimental Rheumatology|April 24, 2010
Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)Christopher Schneeweis, Michael Rafalowicz, Eugen Feist, et al.
Arthritis Research & Therapy|January 28, 2014
Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational studyGerd R Burmester, Marco Matucci-Cerinic, Xavier Mariette, et al.
Arthritis Research|July 11, 2002
Analysis of immunoglobulin light chain rearrangements in the salivary gland and blood of a patient with Sjögren's syndromeAnnett M Jacobi, Arne Hansen, Olaf Kaufmann, et al.
Journal of Biomolecular Screening|March 24, 2007
Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugsThomas Häupl, Mehdi Yahyawi, Carsten Lübke, et al.
European Journal of Immunology|August 30, 2017
Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritisSarah Fleischer, Stefanie Ries, Ping Shen, et al.
Pageof 30